Search results for " biotherapeutic"

Article Improving PAT for Biologics
Because bioprocesses are complex and dependent on multi-factor interactions between the process variables, using PAT for biotherapeutics can be more challenging than for small-molecule drug manufactur…

Article Optimizing Resin Performance with Disposable Chromatography Solutions
…y resins (including affinity resins based on Protein L) for the purification of a next-generation of biotherapeutics such as antibody fragments. Tingley (Repligen): Yes, the single-use chromatogr…

Article Viral Clearance Challenges in Bioprocessing
…cular importance because there is often pressure to limit operations to those that are necessary for biotherapeutic purification rather than include operations that confer a marginal improvement of p…

Article Challenges and Trends in Biopharma Facility Design
Kranjac (Cytiva): As bioprocess infrastructure transitions from large facilities, which traditionally produce only one biotherapeutic, biopharmaceutical companies are increasingly seeking flexibility …

Article Predicting Progress in Protein Aggregation
“The formulation readiness of protein-based drugs--or their formulability--can be an issue, particularly for biotherapeutics that must be administered in high concentrations. Because there are too man…

Article Biotechnology Innovation and Growth in Israel
In 2009, Pfizer partnered with Protalix Biotherapeutics and together developed the first approved plant-based biologic for treating type 1 Gaucher’s disease (11). In 2011, Merck KGaA’s subsidiary Merc…

Previous Page